menu search

MGCLF / MGC Pharmaceuticals records strongest ever quarterly sales; Cognicann phase II trial delayed

MGC Pharmaceuticals records strongest ever quarterly sales; Cognicann phase II trial delayed
MGC Pharmaceutical Ltd said it achieved its strongest quarterly sales to date in the three months to end-December, driven by its COVID-19 treatment ArtemiC. The phytomedicines company also announced that the phase II clinical trial for Cognicann, its Investigational Medicinal Product (IMP) designed to treat patients with dementia and Alzheimer's disease, which is undertaken by the University of Notre Dame in Perth, Western Australia, has been delayed after logistics problems impacted the supply of the product to into Australia, while COVID-19 restrictions have hampered access to trial participants. Read More
Posted: Jan 31 2022, 06:21
Author Name: Proactive Investors
Views: 110888

MGCLF News  

MGC Pharmaceuticals clarifies share consolidation and new fundraise

By Proactive Investors
November 1, 2023

MGC Pharmaceuticals clarifies share consolidation and new fundraise

MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) has provided clarity on the company's consolidation of capital and new fundraising programme. Fu more_horizontal

MGC Pharmaceuticals proposes financial and capital restructuring plan

By Proactive Investors
September 26, 2023

MGC Pharmaceuticals proposes financial and capital restructuring plan

MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) said directors have been forced to propose a financial and capital restructuring plan to secure more_horizontal

MGC Pharmaceuticals hails pivot to medical products, legacy sales hit

By Proactive Investors
August 31, 2023

MGC Pharmaceuticals hails pivot to medical products, legacy sales hit

MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) hailed a "year of great productivity" as it pivoted to medicinal products, with legacy sales hit more_horizontal

MGC Pharmaceuticals proposes fundraising for Australian investors

By Proactive Investors
August 1, 2023

MGC Pharmaceuticals proposes fundraising for Australian investors

MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) said it is looking to raise up to A$2.7 million (£1.39 million) via a share purchase plan for more_horizontal

MGC Pharma hails good quarter as UK patients get CannEpil

By Proactive Investors
July 28, 2023

MGC Pharma hails good quarter as UK patients get CannEpil

MGC Pharma said it has seen good momentum in its latest quarter with CannEpil, its Investigational Medicinal Product now available in the UK by Named more_horizontal

Small-cap movers: MGC Pharma, Versarien and the end of cheap money

By Proactive Investors
July 14, 2023

Small-cap movers: MGC Pharma, Versarien and the end of cheap money

The era of cheap money is well and truly behind us. Nobody understands this more than the UK small caps, who are finding it increasingly harder and pr more_horizontal

MGC Pharmaceuticals raises £0.7mln for working capital

By Proactive Investors
July 14, 2023

MGC Pharmaceuticals raises £0.7mln for working capital

MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) has raised £0.7mln (A$1.34mln) via a placing and subscription as well as a loan to bridge the c more_horizontal

MGC Pharmaceuticals clarifies shape of recent AMC Pharma order

By Proactive Investors
July 12, 2023

MGC Pharmaceuticals clarifies shape of recent AMC Pharma order

MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) confirmed that it is receiving an immediate downpayment of US$150,000 as part of last week's US$ more_horizontal


Search within

Pages Search Results: